PURPOSE: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. PATIENTS AND METHODS: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. RESULTS: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. CONCLUSION: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.
PURPOSE: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. PATIENTS AND METHODS: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. RESULTS: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. CONCLUSION: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.
Authors: Henk M Lokhorst; Bronno van der Holt; Jan J Cornelissen; Marie José Kersten; Marinus van Oers; Reinier Raymakers; Monique C Minnema; Sonja Zweegman; Gerard Bos; Nicolaas Schaap; Shulamiet Wittebol; Okke de Weerdt; Rianne Ammerlaan; Pieter Sonneveld Journal: Haematologica Date: 2015-09-04 Impact factor: 9.941
Authors: Heinz Ludwig; Pieter Sonneveld; Faith Davies; Joan Bladé; Mario Boccadoro; Michele Cavo; Gareth Morgan; Javier de la Rubia; Michel Delforge; Meletios Dimopoulos; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Philippe Moreau; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Roman Hajek; Pia Sondergeld; Antonio Palumbo Journal: Oncologist Date: 2014-07-25
Authors: Shaji Kumar; Mei-Jie Zhang; Peigang Li; Angela Dispenzieri; Gustavo A Milone; Sagar Lonial; Amrita Krishnan; Angelo Maiolino; Baldeep Wirk; Brendan Weiss; César O Freytes; Dan T Vogl; David H Vesole; Hillard M Lazarus; Kenneth R Meehan; Mehdi Hamadani; Michael Lill; Natalie S Callander; Navneet S Majhail; Peter H Wiernik; Rajneesh Nath; Rammurti T Kamble; Ravi Vij; Robert A Kyle; Robert Peter Gale; Parameswaran N Hari Journal: Blood Date: 2011-06-20 Impact factor: 22.113
Authors: F Sahebi; S Iacobelli; A V Biezen; L Volin; P Dreger; M Michallet; P T Ljungman; T de Witte; A Henseler; N P M Schaap; L López-Corral; X Poire; J Passweg; R-M Hamljadi; S H Thomas; S Schonland; G Gahrton; C Morris; N KrÖger; L Garderet Journal: Bone Marrow Transplant Date: 2015-03-23 Impact factor: 5.483